MARKET

ELTX

ELTX

Elicio Therapeutics, Inc.
NASDAQ
8.00
-0.07
-0.87%
After Hours: 8.00 0 0.00% 16:10 12/29 EST
OPEN
8.07
PREV CLOSE
8.07
HIGH
8.07
LOW
7.80
VOLUME
106.46K
TURNOVER
--
52 WEEK HIGH
12.62
52 WEEK LOW
4.600
MARKET CAP
139.92M
P/E (TTM)
-2.5373
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ELTX last week (1222-1226)?
Weekly Report · 22h ago
Weekly Report: what happened at ELTX last week (1215-1219)?
Weekly Report · 12/22 09:56
Elicio Therapeutics reports inducement grants
TipRanks · 12/16 13:15
Elicio Therapeutics Grants Stock Options to New Employees
Reuters · 12/16 13:00
Weekly Report: what happened at ELTX last week (1208-1212)?
Weekly Report · 12/15 10:02
Elicio Therapeutics’ ELI-002 7P shows antigen spreading in Phase 2 trial
TipRanks · 12/11 13:16
Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Regeneron (REGN) and Elicio Therapeutics (ELTX)
TipRanks · 12/11 13:10
Elicio Therapeutics Announces That Analysis Of Subset Of Patients In Ongoing Phase 2 AMPLIFY-7P Trial Shows That Majority Of Evaluated Patients Treated With ELI-002 7P Induced Antigen Spreading Targeting Non-mKRAS Neoantigens That Are Not Present In ELI-002 7P Targeted Immunotherapy
Benzinga · 12/11 13:04
More
About ELTX
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.

Webull offers Angion Biomedica Corp stock information, including NASDAQ: ELTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ELTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ELTX stock methods without spending real money on the virtual paper trading platform.